The role of vitamins in cancer: A review

Nutrition and Cancer

Volumn 63, Issue 4, 2011, Pages 479-494

  Mamede, Ana Catarina ^a,b   Tavares, Sonia Dorilde ^a,c   Abrantes, Ana Margarida ^a   Trindade, Joana ^a,c   Maia, Jorge Manuel ^d   Botelho, Maria Filomena ^a,e  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF BEIRA INTERIOR   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d UNIVERSITY OF BEIRA INTERIOR   (Portugal)

^e UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

6 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 2 NAPHTHOIC ACID; 7 (3,5 DI TERT BUTYLPHENYL) 3 METHYL 2,4,6 OCTATRIENOIC ACID; ACETYLCYSTEINE; ALITRETINOIN; ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; ASCORBIC ACID; BEXAROTENE; BIOTIN; CYANOCOBALAMIN; FENRETINIDE; FOLIC ACID; ISOTRETINOIN; MULTIVITAMIN; NICOTINAMIDE; NICOTINIC ACID; PANTOTHENIC ACID; PYRIDOXINE; RECEPTOR BLOCKING AGENT; RETINOIC ACID; RETINOID; RETINOL; RIBOFLAVIN; RO 41 5253; THIAMINE; THIOTEPA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN B COMPLEX; VITAMIN D; VITAMIN K GROUP;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CELL CYCLE ARREST; CHEMICAL CARCINOGENESIS; CHEMOPROPHYLAXIS; COLON CANCER; COLORECTAL ADENOMA; COLORECTAL CANCER; CYANOCOBALAMIN DEFICIENCY; DIGESTIVE SYSTEM CANCER; DRUG BIOAVAILABILITY; DRUG CARCINOGENICITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; ENDOMETRIUM CANCER; EPIDERMOID TUMOR; ESOPHAGUS CANCER; FOLIC ACID BLOOD LEVEL; FOLIC ACID DEFICIENCY; HEAD AND NECK CANCER; HEAD CANCER; HEMATOLOGIC MALIGNANCY; HEPATITIS; HUMAN; LARYNX CANCER; LEUKEMIA; LIVER CANCER; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHOMA; MOUTH CARCINOMA; NASOPHARYNX CANCER; NEUROBLASTOMA; NONHUMAN; OVARY CANCER; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; PYRIDOXINE DEFICIENCY; RECEPTOR AFFINITY; RECEPTOR UPREGULATION; REVIEW; RIBOFLAVIN DEFICIENCY; RISK REDUCTION; SKIN CANCER; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; TERATOGENICITY; THYROID CANCER; TUMOR PROMOTION; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VITAMIN BLOOD LEVEL; VITAMIN INTAKE; VITAMIN SUPPLEMENTATION;

ASCORBIC ACID; CHEMOPREVENTION; DIETARY SUPPLEMENTS; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VITAMIN A; VITAMIN B COMPLEX; VITAMIN D; VITAMIN E; VITAMIN K; VITAMINS;

EID: 79957591415     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2011.539315     Document Type: Review

References (209)

1. Lee KW, Lee HJ, Surh YJ, and Lee CY: Vitamin C and cancer chemoprevention: reappraisal. Am J Clin Nutr 78, 1074-1078, 2003.
2. Young VR and Newberne PM: Vitamins and cancer prevention: issues and dilemmas. Cancer 47(Suppl), 1226-1240, 1981. (Pubitemid 11159600)
3. Smith W and Saba N: Retinoids as chemoprevention for head and neck cancer: where do we go from here? Critical Rev Oncol Hematol 55, 143-152, 2005.
4. Sun SY and Lotan R: Retinoids and their receptors in cancer development and chemoprevention. Critical Rev Oncol Hematol 41, 41-55, 2002.
5. Wolbach SB and Howe PR: Tissue changes following deprivation of fat-soluble A vitamin. J Experimental Med 42, 753-777, 1925.
6. Lasnitzki I: The influence of A hypervitaminosis on the effect of 20- methylcholanthrene on mouse prostate glands grown in vitro. Br J Cancer 9, 434-441, 1955.
7. Zhang D, Holmes WF, Wu S, Soprano DR, and Soprano KJ: Retinoids and ovarian cancer. J Cell Physiol 185, 1-20, 2000.
8. Trump DL: Retinoids in bladder, testis and prostate cancer: epidemiologic, pre-clinical and clinical observations. Leukemia 8(Suppl 3), S50-S54, 1994.
9. Lotan R: Retinoids and apoptosis: implications for cancer chemoprevention and therapy. J Natl Cancer Inst 87, 1655-1657, 1995.
10. Fontana JA and Rishi AK: Classical and novel retinoids: their targets in cancer therapy. Leukemia 16, 463-472, 2002.
11. Mira YLR, Zheng WL, Kuppumbatti YS, Rexer B, Jing Y, et al.: Retinol conversion to retinoic acid is impaired in breast cancer cell lines relative to normal cells. J Cell Physiol 185, 302-309, 2000.
12. Williams SJ, Cvetkovic D, and Hamilton TC: Vitamin A metabolism is impaired in human ovarian cancer. Gynecol Oncol 112, 637-645, 2009.
13. Kristal AR: Vitamin A, retinoids and carotenoids as chemopreventive agents for prostate cancer. J Urol 171(Pt. 2), S54-S58; discussion S58, 2004.
14. Poulain S, Evenou F, Carre MC, Corbel S, Vignaud JM, et al.: Vitamin A/retinoids signalling in the human lung. Lung Cancer 66, 1-7, 2009.
15. Lotan R, Xu XC, Lippman SM, Ro JY, Lee JS, et al.: Suppression of retinoic acid receptor-beta in premalignant oral lesions and its upregulation by isotretinoin. N Engl J Med 332, 1405-1410, 1995.
16. Lotan Y, Xu XC, Shalev M, Lotan R, Williams R, et al.: Differential expression of nuclear retinoid receptors in normal and malignant prostates. J Clin Oncol 18, 116-121, 2000. (Pubitemid 30036344)
17. Hong WK, Endicott J, Itri LM, Doos W, Batsakis JG, et al.: 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 315, 1501-1505, 1986. (Pubitemid 17052146)
18. Beenken SW, Huang P, Sellers M, Peters G, Listinsky C, et al.: Retinoid modulation of biomarkers in oral leukoplakia/dysplasia. J Cell Biochem Suppl 19, 270-277, 1994. (Pubitemid 24306479)
19. Wada RK, Pai DS, Huang J, Yamashiro JM, and Sidell N: Interferon-gamma and retinoic acid down-regulate N-myc in neuroblastoma through complementary mechanisms of action. Cancer Lett 121, 181-188, 1997. (Pubitemid 28008917)
20. Rook AH, Jaworsky C, Nguyen T, Grossman RA, Wolfe JT, et al.: Beneficial effect of low-dose systemic retinoid in combination with topical tretinoin for the treatment and prophylaxis of premalignant and malignant skin lesions in renal transplant recipients. Transplantation 59, 714-719, 1995.
21. Meyskens FL, Jr., and Manetta A: Prevention of cervical intraepithelial neoplasia and cervical cancer. Am J Clin Nutr 62(Suppl), 1417S-1419S, 1995.
22. Bassi V, Vitale M, Feliciello A, De Riu S, Rossi G, et al.: Retinoic acid induces intercellular adhesion molecule-1 hyperexpression in human thyroid carcinoma cell lines. J Clin Endocrinol Metab 80, 1129-1135, 1995.
23. Van Herle AJ, Agatep ML, Padua DN III, Totanes TL, Canlapan DV, et al.: Effects of 13 cis-retinoic acid on growth and differentiation of human follicular carcinoma cells (UCLA R0 82 W-1) in vitro. J Clin Endocrinol Metab 71, 755-763, 1990.
24. Roman SD, Clarke CL, Hall RE, Alexander IE, and Sutherland RL: Expression and regulation of retinoic acid receptors in human breast cancer cells. Cancer Res 52, 2236-2242, 1992.
25. Roman SD, Ormandy CJ, Manning DL, Blamey RW, Nicholson RI, et al.: Estradiol induction of retinoic acid receptors in human breast-cancer cells. Cancer Res 53, 5940-5945, 1993. (Pubitemid 24006164)
26. Vanderburg B, Vanderleede BJM, Kwakkenbosisbrucker L, Salverda S, Delaat SW, et al.: Retinoic acid resistance of estradiol-independent breastcancer cells coincides with diminished retinoic acid receptor function. Mol Cellular Endocrinol 91, 149-157, 1993.
27. Paik SM: Clinical-significance of Erbb-2 (Her-2/Neu) protein. Cancer Investigation 10, 575-579, 1992.
28. Offterdinger M, Schneider SM, Huber H, and Grunt TW: Expression of c-erbB-4/HER4 is regulated in T47D breast carcinoma cells by retinoids and vitamin D-3. Biochem Biophys Res Comm 258, 559-564, 1999. (Pubitemid 29290307)
29. Seewaldt VL, Dietze EC, Johnson BS, Collins SJ, and Parker MB: Retinoic acid-mediated G1-S-phase arrest of normal human mammary epithelial cells is independent of the level of p53 protein expression. Cell Growth Differ 10, 49-59, 1999. (Pubitemid 29086919)
30. Gottardis MM, Bischoff ED, Shirley MA, Wagoner MA, Lamph WW, et al.: Chemoprevention ofmammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res 56, 5566-5570, 1996. (Pubitemid 26422151)
31. Webber MM, Bello-DeOcampo D, Quader S, Deocampo ND, Metcalfe WS, et al.: Modulation of the malignant phenotype of human prostate cancer cells by N-(4-hydroxyphenyl)retinamide (4-HPR). Clin Exp Metastasis 17, 255-263, 1999. (Pubitemid 29360904)
32. Sharp RM, Bello-DeOcampo D, Quader ST, and Webber MM: N-(4- hydroxyphenyl)retinamide (4-HPR) decreases neoplastic properties of human prostate cells: an agent for prevention. Mutat Res 496, 163-170, 2001. (Pubitemid 32718778)
33. Sun SY, Yue P, Mao L, Dawson MI, Shroot B, et al.: Identification of receptor-selective retinoids that are potent inhibitors of the growth of human head and neck squamous cell carcinoma cells. Clin Cancer Res 6, 1563-1573, 2000. (Pubitemid 30226247)
34. Ren J: Comparison between synthetic retinoid CD437 and acitretin inhibiting melanoma A375 cell in vitro. J Nanjing Med Univ 22, 87-91, 2008.
35. Gonda K, Tsuchiya H, Sakabe T, Akechi Y, Ikeda R, et al.: Synthetic retinoid CD437 induces mitochondria-mediated apoptosis in hepatocellular carcinoma cells. Biochem Biophys Res Commun 370, 629-633, 2008.
36. Shalinsky DR, Bischoff ED, Lamph WW, Zhang L, Boehm MF, et al.: A novel retinoic acid receptor-selective retinoid, ALRT1550, has potent antitumor activity against human oral squamous carcinoma xenografts in nude mice. Cancer Res 57, 162-168, 1997. (Pubitemid 27020347)
37. Toma S, Emionite L, Scaramuccia A, Ravera G, and Scarabelli L: Retinoids and human breast cancer: in vivo effects of an antagonist for RAR-alpha. Cancer Lett 219, 27-31, 2005. (Pubitemid 40203167)
38. Toma S, Isnardi L, Raffo P, Riccardi L, Dastoli G, et al.: RARalpha antagonist Ro 41-5253 inhibits proliferation and induces apoptosis in breast-cancer cell lines. Int J Cancer 78, 86-94, 1998. (Pubitemid 28391678)
39. Eckhardt K and Schmitt G: A retinoic acid receptor alpha antagonist counteracts retinoid teratogenicity in vitro and reduced incidence and/or severity of malformations in vivo. Toxicol Lett 70, 299-308, 1994. (Pubitemid 24049763)
40. Prasad KN, Cole WC, Kumar B, and Prasad KC: Scientific rationale for using high-dose multiple micronutrients as an adjunct to standard and experimental cancer therapies. J Am Coll Nutr 20(Suppl), 450S-463S; discussion 473S-475S, 2001.
41. van Zandwijk N, Dalesio O, Pastorino U, de Vries N, and van Tinteren H: EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst 92, 977-986, 2000.
42. Glynn SA and Albanes D: Folate and cancer: a review of the literature. Nutr Cancer 22, 101-119, 1994. (Pubitemid 24310119)
43. Ames BN: DNA damage from micronutrient deficiencies is likely to be a major cause of cancer. Mutat Res 475, 7-20, 2001.
44. van Poppel G and Van Den Berg H: Vitamins and cancer. Cancer Lett 114, 195-202, 1997.
45. Fenech M: Micronucleus frequency in human lymphocytes is related to plasma vitamin B12 and homocysteine. Mutat Res 428, 299-304, 1999.
46. Kim YI: Nutritional epigenetics: impact of folate deficiency on DNA methylation and colon cancer susceptibility.JNutr 135, 2703-2709, 2005.
47. Mason JB and Levesque T: Folate: effects on carcinogenesis and the potential for cancer chemoprevention. Oncology (Williston Park) 10, 1727-1736, 1742-1723; discussion 1743-1724, 1996.
48. Kim YI: Will mandatory folic acid fortification prevent or promote cancer? Am J Clin Nutr 80, 1123-1128, 2004.
49. Rogers AE: Methyl donors in the diet and responses to chemical carcinogens. Am J Clin Nutr 61, S659-S665, 1995.
50. Selhub J, Jacques PF, Wilson PWF, Rush D, and Rosenberg IH: Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 270, 2693-2698, 1993. (Pubitemid 23350966)
51. Tully DB, Allgood VE, and Cidlowski JA: Modulation of steroid receptormediated gene-expression by vitamin-B-6. FASEB J 8, 343-349, 1994. (Pubitemid 24098357)
52. Sellers TA, Kushi LH, Cerhan JR, Vierkant RA, Gapstur SM, et al.: Dietary folate intake, alcohol, and risk of breast cancer in a prospective study of postmenopausal women. Epidemiology 12, 420-428, 2001. (Pubitemid 32566484)
53. Negri E, La Vecchia C, and Franceschi S: Re: dietary folate consumption and breast cancer risk. J Nat Cancer Inst 92, 1270-1271, 2000. (Pubitemid 30627736)
54. Levi F, Pasche C, Lucchini F, and La Vecchia C: Dietary intake of selected micronutrients and breast-cancer risk. Int J Cancer 91, 260-263, 2001. (Pubitemid 32041750)
55. Zhang SM, Willett WC, Selhub J, Hunter DJ, Giovannucci EL, et al.: Plasma folate, vitamin B6, vitamin B12, homocysteine, and risk of breast cancer. J Natl Cancer Inst 95, 373-380, 2003. (Pubitemid 36395257)
56. Lajous M, Lazcano-Ponce E, Hernandez-Avila M, Willett W, and Romieu I: Folate, vitamin B-6, and vitamin B-12 intake and the risk of breast cancer among Mexican women. Cancer Epidemiol Biomarkers Prev 15, 443-448, 2006.
57. Hultdin J, Van Guelpen B, Bergh A, Hallmans G, and Stattin M: Plasma folate, vitamin B12, and homocysteine and prostate cancer risk: a prospective study. Int J Cancer 113, 819-824, 2005. (Pubitemid 40101265)
58. Johansson M, Appleby PN, Allen NE, Travis RC, Roddam AW, et al.: Circulating concentrations of folate and vitamin B-12 in relation to prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition study. Cancer Epidemiol Biomarkers Prev 17, 279-285, 2008. (Pubitemid 351272776)
59. Figueiredo JC, Grau MV, Haile RW, Sandler RS, Summers RW, et al.: Folic acid and risk of prostate cancer: results from a randomized clinical trial. J Natl Cancer Inst 101, 432-435, 2009.
60. Key TJA, Silcocks PB, Davey GK, Appleby PN, and Bishop DT: A case-control study of diet and prostate cancer. Br J Cancer 76, 678-687, 1997. (Pubitemid 27354685)
61. Cole BF, Baron JA, Sandler RS, Haile RW, Ahnen DJ, et al.: Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA 297, 2351-2359, 2007. (Pubitemid 46883748)
62. Kim Y and Mason JB: Folate, epithelial dysplasia and colon cancer. Proc Assoc Am Physicians 107, 218-227, 1995.
63. Giovannucci E: Modifiable risk factors for colon cancer. Gastroenterol Clin North Am 31, 925-943, 2002.
64. Glynn SA, Albanes D, Pietinen P, Brown CC, Rautalahti M, et al.: Colorectal cancer and folate status: a nested case-control study among male smokers. Cancer Epidemiol Biomarkers Prev 5, 487-494, 1996. (Pubitemid 26235013)
65. Giovannucci E, Rimm EB, Ascherio A, Stampfer MJ, Colditz GA, et al.: Alcohol, low-methionine low-folate diets, and risk of colon-cancer in men. J Nat Cancer Inst 87, 265-273, 1995.
66. Glynn SA and Albanes D: Folate and cancer: a review of the literature. Nutr Cancer 22, 101-119, 1994. (Pubitemid 24310119)
67. Giovannucci E, Stampfer MJ, Colditz GA, Hunter DJ, Fuchs C, et al.: Multivitamin use, folate, and colon cancer in women in the Nurses' Health Study. Ann Internal Med 129, 517-524, 1998. (Pubitemid 28460290)
68. Chandy S: Effect of vitamin B12 and folate on homocysteine levels in colorectal cancer. Indian J Clin Biochem 23, 258-261, 2008.
69. Dahlin AM, Van Guelpen B, Hultdin J, Johansson I, Hallmans G, et al.: Plasma vitamin B12 concentrations and the risk of colorectal cancer: A nested case-referent study. Int J Cancer 122, 2057-2061, 2008. (Pubitemid 351441196)
70. Zhang ZF, Kurtz RC, Yu GP, Sun M, Gargon N, et al.: Adenocarcinomas of the esophagus and gastric cardia: The role of diet. Nutr Cancer 27, 298-309, 1997. (Pubitemid 27161529)
71. Heimburger DC: Localized deficiencies of folic-acid in aerodigestive tissues. Ann NY Acad Sci 669, 87-96, 1992.
72. Mayne ST, Risch HA, Dubrow R, Chow WH, Gammon MD, et al.: Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 10,1055-1062, 2001. (Pubitemid 32959152)
73. Lavecchia C, Ferraroni M, Davanzo B, Decarli A, and Franceschi S: Selected micronutrient intake and the risk of gastric cancer. Cancer Epidemiol Biomarkers Prev 3, 393-398, 1994. (Pubitemid 24221448)
74. Harrison LE, Zhang ZF, Karpeh MS, Sun M, and Kurtz RC: The role of dietary factors in the intestinal and diffuse histologic subtypes of gastric adenocarcinoma: a case-control study in the U.S. Cancer 80, 1021-1028, 1997. (Pubitemid 27427600)
75. Krumdieck CL: Localized folate-deficiency and cancer. Vit Cancer Prev 14, 39-49, 1991.
76. Nacci A, Dallan I, Bruschini L, Traino AC, Panicucci E, et al.: Plasma homocysteine, folate, and vitamin B12 levels in patients with laryngeal cancer. Arch Otolaryngol Head Neck Surg 134, 1328-1333, 2008.
77. Byar D and Blackard C: Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancer. Urology 10, 556-561, 1977. (Pubitemid 8236410)
78. Newling DW, Robinson MR, Smith PH, Byar D, Lockwood R, et al.: Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group. EORTC Genito-Urinary Tract Cancer Cooperative Group. Eur Urol 27, 110-116, 1995.
79. Lattouf JB: Chemoprevention in bladder cancer: what's new? Can Urol Assoc J 3(Suppl 4), S184-S187, 2009.
80. Pais RC, Vanous E, Hollins B, Faraj BA, Davis R, et al.: Abnormal vitamin B6 status in childhood leukemia. Cancer 66, 2421-2428, 1990.
81. Kim YI: Folate: a magic bullet or a double edged sword for colorectal cancer prevention? Gut 55, 1387-1389, 2006.
82. Ulrich CM and Potter JD: Folate supplementation: too much of a good thing? Cancer Epidemiol Biomarkers Prev 15, 189-193, 2006.
83. Ulrich CM and Potter JD: Folate and cancer-timing is everything. JAMA 297, 2408-2409, 2007.
84. Kim YI: Folate and colorectal cancer: an evidence-based critical review. Mol Nutr Food Res 51, 267-292, 2007.
85. Lee WN, Boros LG, Puigjaner J, Bassilian S, Lim S, et al.: Mass isotopomer study of the nonoxidative pathways of the pentose cycle with [1,2-13C2]glucose. Am J Physiol 274(Pt. 1), E843-E851, 1998.
86. Boros LG, Puigjaner J, Cascante M, Lee WN, Brandes JL, et al.: Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and tumor cell proliferation. Cancer Res 57, 4242-4248, 1997. (Pubitemid 27413432)
87. Cascante M, Centelles JJ, Veech RL, Lee WN, and Boros LG: Role of thiamin (vitamin B-1) and transketolase in tumor cell proliferation. Nutr Cancer 36, 150-154, 2000. (Pubitemid 30437034)
88. Comin-Anduix B, Boren J, Martinez S, Moro C, Centelles JJ, et al.: The effect of thiamine supplementation on tumour proliferation. A metabolic control analysis study. Eur J Biochem 268, 4177-4182, 2001. (Pubitemid 32862878)
89. Liu S, Stromberg A, Tai HH, and Moscow JA: Thiamine transporter gene expression and exogenous thiamine modulate the expression of genes involved in drug and prostaglandin metabolism in breast cancer cells. Mol Cancer Res 2, 477-487, 2004. (Pubitemid 39121510)
90. Rivlin RS: Riboflavin and cancer: a review. Cancer Res 33, 1977-1986, 1973.
91. Rao PN, Levine E, Myers MO, Prakash V, Watson J, et al.: Elevation of serum riboflavin carrier protein in breast cancer. Cancer Epidemiol Biomarkers Prev 8, 985-990, 1999. (Pubitemid 29536091)
92. Holm J, Hansen SI, Sondergaard K, and Hoier-Madsen M: The high-affinity folate binding protein in normal and malignant mammary gland tissue. Adv Exp Med Biol 338, 757-760, 1993. (Pubitemid 23340693)
93. Foy H, Kondi A, and Verjee ZH: Relation of riboflavin deficiency to corticosteroid metabolism and red cell hypoplasia in baboons. J Nutr 102, 571-582, 1972.
94. Foy H and Kondi A: The vulnerable esophagus: riboflavin deficiency and squamous cell dysplasia of the skin and the esophagus. J Natl Cancer Inst 72, 941-948, 1984. (Pubitemid 14131738)
95. Siassi F, Pouransari Z, and Ghadirian P: Nutrient intake and esophageal cancer in the Caspian littoral of Iran: a case-control study. Cancer Detect Prev 24, 295-303, 2000. (Pubitemid 30656738)
96. Pangrekar J, Krishnaswamy K, and Jagadeesan V: Effects of riboflavin deficiency and riboflavin administration on carcinogen-DNA binding. Food Chem Toxicol 31, 745-750, 1993. (Pubitemid 23316251)
97. Liu T, Soong SJ, Wilson NP, Craig CB, Cole P, et al.: A case control study of nutritional factors and cervical dysplasia. Cancer Epidemiol Biomarkers Prev 2, 525-530, 1993.
98. Vaidya SM, Kamlakar PL, and Kamble SM: Molybdenum, xanthine oxidase and riboflavin levels in tamoxifen treated postmenopausal women with breast cancer. Indian J Med Sci 52, 244-247, 1998.
99. Tsao SM, Yin MC, and Liu WH: Oxidant stress and B vitamins status in patients with non-small cell lung cancer. Nutr Cancer 59, 8-13, 2007.
100. Hirakawa N, Okauchi R, Miura Y, and Yagasaki K: Anti-invasive activity of niacin and trigonelline against cancer cells. Biosci Biotechnol Biochem 69, 653-658, 2005. (Pubitemid 40589132)
101. Heaney ML, Gardner JR, Karasavvas N, Golde DW, Scheinberg DA, et al.: Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res 68, 8031-8038, 2008.
102. Rivas CI, Zuniga FA, Salas-Burgos A, Mardones L, Ormazabal V, et al.: Vitamin C transporters. J Physiol Biochem 64, 357-375, 2008.
103. Verrax J and Calderon PB: The controversial place of vitamin C in cancer treatment. Biochem Pharmacol 76, 1644-1652, 2008.
104. Fruehauf JP and Meyskens FL: Reactive oxygen species: a breath of life or death? Clin Cancer Res 13, 789-794, 2007.
105. Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, et al.: Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice: editorial comment. J Urol 181, 2384-2385, 2009.
106. Rozanova N, Zhang JZ, and Heck DE: Catalytic Therapy of cancer with ascorbate and extracts of medicinal herbs. Evide-Based Complement Alternative Med 7, 203-212, 2010.
107. Chen Q, Espey MG, Sun AY, Lee JH, Krishna MC, et al.: Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Nat Acad Sciences USA 104, 8749-8754, 2007. (Pubitemid 47175383)
108. Cameron E and Pauling L: The orthomolecular treatment of cancer: I. The role of ascorbic acid in host resistance. Chem Biol Interact 9, 273-283, 1974.
109. Cameron E and Campbell A: The orthomolecular treatment of cancer: II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem Biol Interact 9, 285-315, 1974.
110. Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, et al.: Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol 19, 1969-1974, 2008.
111. Rozanova N, Zhang JZ, and Heck DE: Catalytic therapy of cancer with ascorbate and extracts of medicinal herbs. Evid Based Complement Alternat Med 7, 203-212, 2007.
112. Toohey JI: Dehydroascorbic acid as an anti-cancer agent. Cancer Lett 263, 164-169, 2008.
113. Heaney ML, Gardner JR, Karasavvas N, Golde DW, Scheinberg DA, et al.: Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res 68, 8031-8038, 2008.
114. Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, et al.: Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Nat Acad Sci USA 105, 11105-11109, 2008.
115. Kuroiwa Y, Yamada M, Matsui K, Okamura T, Ishii Y, et al.: Combined ascorbic acid and sodium nitrite treatment induces oxidative DNA damage-associated mutagenicity in vitro, but lacks initiation activity in rat forestomach epithelium. Toxicol Sci 104, 274-282, 2008. (Pubitemid 352038250)
116. Verrax J and Calderon PB: Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic Biol Med 47, 32-40, 2009.
117. Yeom CH, Lee G, Park JH, Yu J, Park S, et al.: High dose concentration administration of ascorbic acid inhibits tumor growth in BALB/Cmice implanted with sarcoma 180 cancer cells via the restriction of angiogenesis. J Transl Med 7, 70, 2009.
118. Gandini S, Raimondi S, Gnagnarella P, Dore JF, Maisonneuve P, et al.: Vitamin D and skin cancer: a meta-analysis. Eur J Cancer 45, 634-641, 2009.
119. John EM, Schwartz GG, Koo J, Van Den Berg D, and Ingles SA: Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer. Cancer Res 65, 5470-5479, 2005. (Pubitemid 40827360)
120. Hoogendijk WJG, Lips P, Dik MG, Deeg DJH, Beekman ATF, et al.: Depression is associated with decreased 25-hydroxyvitamin D and increased parathyroid hormone levels in older adults. Arch Gen Psych 65, 508-512, 2008. (Pubitemid 351645046)
121. Pendas-Franco N, Gonzalez-Sancho JM, Suarez Y, Aguilera O, Steinmeyer A, et al.: Vitamin D regulates the phenotype of human breast cancer cells. Differentiation 75, 193-207, 2007. (Pubitemid 46426618)
122. Roy D, Calaf G, and Hei TK: Role of vitamin D receptor gene in radiation-induced neoplastic transformation of human breast epithelial cell. Steroids 68, 621-627, 2003. (Pubitemid 37080583)
123. Zehnder D, Bland R, Williams MC, McNinch RW, Howie AJ, Set al.: Extrarenal expression of 25-hydroxyvitamin D-3-1 alpha-hydroxylase. J Clin Endocrinol Metabolism 86, 888-894, 2001. (Pubitemid 32207511)
124. Corder EH, Guess HA, Hulka BS, Friedman GD, Sadler M, et al.:Vitamin-D and prostate-cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 2, 467-472, 1993.
125. Holick MF: Vitamin D deficiency. New Eng J Med 357, 266-281, 2007.
126. Uitterlinden AG, Fang Y, van Meurs JBJ, Pols HAP, and van Leeuwen JPTM: Genetics and biology of vitamin D receptor polymorphisms. Gene 338, 143-156, 2004. (Pubitemid 39094759)
127. Lundin AC, Soderkvist P, Eriksson B, Bergman-Jungestrom M, Wingren S, et al.: Association of breast cancer progression with a vitamin D receptor gene polymorphism. Cancer Res 59, 2332-2334, 1999. (Pubitemid 29242278)
128. Lowe LC, Guy M, Mansi JL, Peckitt C, Bliss J, et al.: Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype, and breast cancer risk in a UK Caucasian population. Eur Jo Cancer 41, 1164-1169, 2005. (Pubitemid 40725575)
129. Grant WB: An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer 94, 1867-1875, 2002.
130. Zhao XY, Peehl DM, Navone NM, and Feldman D: 1 alpha,25-dihydroxyvitamin D-3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. Endocrinology 141, 2548-2556, 2000. (Pubitemid 32269075)
131. Corder EH, Friedman GD, Vogelman JH, and Orentreich N: Seasonal-variation in vitamin-D, vitamin-D-binding protein, and dehydroepiandrosterone: risk of prostate-cancer in black and white men. Cancer Epidemiol Biomarkers Prev 4, 655-659, 1995.
132. DeLuca HF and Ostrem V: The relationship between the vitamin D system and cancer. Adv Exp Med Biol 206, 413-429, 1986.
133. Hickish T, Cunningham D, Colston K, Millar BC, Sandle J, et al.: The effect of 1,25-dihydroxyvitamin D3 on lymphoma cell lines and expression of vitamin D receptor in lymphoma. Br J Cancer 68, 668-672, 1993. (Pubitemid 23301265)
134. Ahonen MH, Zhuang YH, Aine R, Ylikomi T, and Tuohimaa P: Androgen receptor and vitamin D receptor in human ovarian cancer: growth stimulation and inhibition by ligands. Int J Cancer 86, 40-46, 2000. (Pubitemid 30133984)
135. Fujioka T, Hasegawa M, Ishikura K, Matsushita Y, Sato M, et al.: Inhibition of tumor growth and angiogenesis by vitamin D3 agents in murine renal cell carcinoma. J Urol 160, 247-251, 1998. (Pubitemid 29479470)
136. Vandewalle B, Wattez N, and Lefebvre J: Effects of vitamin D3 derivatives on growth, differentiation and apoptosis in tumoral colonic HT 29 cells: possible implication of intracellular calcium. Cancer Lett 97, 99-106, 1995.
137. Yabushita H, Hirata M, Noguchi M, and Nakanishi M: Vitamin D receptor in endometrial carcinoma and the differentiation-inducing effect of 1,25-dihydroxyvitamin D3 on endometrial carcinoma cell lines. J Obstet Gynaecol Res 22, 529-539, 1996. (Pubitemid 27042086)
138. Zhou W, Suk R, Liu G, Park S, Neuberg DS, et al.: Vitamin D is associated with improved survival in early-stage non-small-cell lung cancer patients. Cancer Epidemiol Biomarkers Prev 14, 2303-2309, 2005. (Pubitemid 41437829)
139. Robsahm TE, Tretli S, Dahlback A, and Moan J: Vitamin D3 from sunlight may improve the prognosis of breast-, colon- and prostate cancer (Norway). Cancer Causes Control 15, 149-158, 2004. (Pubitemid 38445361)
140. Hsu JY, Feldman D, McNeal JE, and Peehl DM: Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res 61, 2852-2856, 2001. (Pubitemid 32691924)
141. Whitlatch LW, Young MV, Schwartz GG, Flanagan JN, Burnstein KL, et al.: 25-Hydroxyvitamin D-1alpha-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. J Steroid Biochem Mol Biol 81,135-140, 2002. (Pubitemid 34876404)
142. Giovannucci E: The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control 16, 83-95, 2005.
143. Feskanich D, Ma J, Fuchs CS, Kirkner GJ, Hankinson SE, et al.: Plasma vitamin D metabolites and risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 13, 1502-1508, 2004. (Pubitemid 39202318)
144. Tworoger SS, Lee IM, Buring JE, Rosner B, Hollis BW, et al.: Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of incident ovarian cancer. Cancer Epidemiol Biomarkers Prev 16, 783-788, 2007. (Pubitemid 46650582)
145. Ahonen MH, Tenkanen L, Teppo L, Hakama M, and Tuohimaa P: Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 11, 847-852, 2000.
146. Gissel T, Rejnmark L, Mosekilde L, and Vestergaard P: Intake of vitamin D and risk of breast cancer - a meta-analysis. J Steroid Biochem Mol Biol 111, 195-199, 2008.
147. Shin MH, Holmes MD, Hankinson SE, Wu K, Colditz GA, et al.: Intake of dairy products, calcium, and vitamin D and risk of breast cancer. J Natl Cancer Inst 94, 1301-1311, 2002.
148. Giovannucci E, Liu Y, Rimm EB, Hollis BW, Fuchs CS, et al.: Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 98, 451-459, 2006.
149. Haussler MR, Haussler CA, Jurutka PW, Thompson PD, Hsieh JC, et al.: The vitamin D hormone and its nuclear receptor: molecular actions and disease states. J Endocrinol 154(Suppl), S57-S73, 1997.
150. Uitterlinden AG, Fang Y, van Meurs JB, van Leeuwen H, and Pols HA: Vitamin D receptor gene polymorphisms in relation to Vitamin D related disease states. J Steroid Biochem Mol Biol 89-90, 187-193, 2004. (Pubitemid 38844281)
151. Sillanpaa P, Hirvonen A, Kataja V, Eskelinen M, Kosma VM, et al.: Vitamin D receptor gene polymorphism as an important modifier of positive family history related breast cancer risk. Pharmacogenetics 14, 239-245, 2004. (Pubitemid 38530515)
152. Taylor JA, Hirvonen A, Watson M, Pittman G, Mohler JL, et al.: Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res 56, 4108-4110, 1996. (Pubitemid 26304998)
153. Ingles SA, Coetzee GA, Ross RK, Henderson BE, Kolonel LN, et al.: Association of prostate cancer with vitamin D receptor haplotypes in African-Americans. Cancer Res 58, 1620-1623, 1998. (Pubitemid 28215081)
154. Huang SP, Chou YH, Chang WSW, Wu MT, Chen YY, et al.: Association between vitamin D receptor polymorphisms and prostate cancer risk in a Taiwanese population. Cancer Letters 207, 69-77, 2004.
155. Oakley-Girvan I, Feldman D, Eccleshall TR, Gallagher RP, Wu AH, et al.: Risk of early-onset prostate cancer in relation to germ line polymorphisms of the vitamin D receptor. Cancer Epidemiol Biomarkers Prev 13, 1325-1330, 2004. (Pubitemid 39071556)
156. Luscombe CJ, Fryer AA, French ME, Liu S, Saxby MF, et al.: Exposure to ultraviolet radiation: associationwith susceptibility and age at presentation with prostate cancer. Lancet 358, 641-642, 2001. (Pubitemid 32786834)
157. Gsur A, Madersbacher S, Haidinger G, Schatzl G, Marberger M, et al.: Vitamin D receptor gene polymorphism and prostate cancer risk. Prostate 51, 30-34, 2002. (Pubitemid 34274857)
158. Tayeb MT, Clark C, Haites NE, Sharp L, Murray GI, et al.: Vitamin D receptor, HER-2 polymorphisms, and risk of prostate cancer in men with benign prostate hyperplasia. Saudi Med J 25, 447-451, 2004.
159. Suzuki K, Matsui H, Ohtake N, Nakata S, Takei T, et al.: Vitamin D receptor gene polymorphism in familial prostate cancer in a Japanese population. Int J Urol 10, 261-266, 2003. (Pubitemid 36609464)
160. Cheteri MB, Stanford JL, Friedrichsen DM, Peters MA, Iwasaki L, et al.: Vitamin D receptor gene polymorphisms and prostate cancer risk. Prostate 59, 409-418, 2004. (Pubitemid 38661808)
161. Slattery M: Variants of the VDR gene and risk of colon cancer (United States). Cancer Causes Control 12, 359-364, 2001.
162. Lamprecht SA and Lipkin M: Cellular mechanisms of calcium and vitamin D in the inhibition of colorectal carcinogenesis. Ann NY Acad Sci 952, 73-87, 2001. (Pubitemid 34060011)
163. Lamprecht SA and Lipkin M: Chemoprevention of colon cancer by calcium, vitamin D and folate: molecular mechanisms. Nat Rev Cancer 3, 601-614, 2003. (Pubitemid 37328832)
164. McCullough ML, Bandera EV, Moore DF, and Kushi LH: Vitamin D and calcium intake in relation to risk of endometrial cancer: a systematic review of the literature. Prev Med 46, 298-302, 2008.
165. Bertone-Johnson ER: Vitamin D and breast cancer. Ann Epidemiol 19, 462-467, 2009.
166. Klein EA, Thompson IM, Lippman SM, Goodman PJ, Albanes D, et al.: SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer Prostatic Dis 3, 145-151, 2000.
167. Klein EA, Thompson IM, Lippman SM, Goodman PJ, Albanes D, et al.: SELECT: the Selenium and vitamin E Cancer Prevention Trial. Urol Oncol Seminars Original Investigations 21, 59-65, 2003. (Pubitemid 41121900)
168. Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, et al.: Effects of longterm supplementation on and cancer vitamin E cardiovascular events: a randomized controlled trial. JAMA 293, 1338-1347, 2005. (Pubitemid 40381486)
169. Traber MG and Atkinson J: Vitamin E, antioxidant, and nothing more. Free Radical Biol Med 43, 4-15, 2007.
170. Azzi A and Stocker A: Vitamin E: non-antioxidant roles. Progress Lipid Res 39, 231-255, 2000. (Pubitemid 30224705)
171. Lippman SM, Goodman PJ, Klein EA, Parnes HL, Thompson IM, et al.: Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Nat Cancer Inst 97, 94-102, 2005. (Pubitemid 40277089)
172. Quin J, Engle D, Litwiller A, Peralta E, Grasch A, et al.: Vitamin E succinate decreases lung cancer tumor growth in mice. J Surg Res 127, 139-143, 2005. (Pubitemid 41080625)
173. Traber MG:Vitamin E regulatory mechanisms. Ann Rev Nutr 27, 347-362, 2007.
174. Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, et al.: Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Nat Cancer Inst 90, 440-446, 1998. (Pubitemid 28160635)
175. Brigelius-Flohe R and Traber MG: Vitamin E: function and metabolism. FASEB J 13, 1145-1155, 1999. (Pubitemid 29300361)
176. Miller ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, et al.: Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Internal Med 142, 37-46, 2005.
177. Mitchel RE and McCann RA: Skin tumor promotion by vitamin E inmice: amplification by ionizing radiation and vitamin C. Cancer Detect Prev 27, 102-108, 2003. (Pubitemid 36429588)
178. Bermudez Y, Ahmadi S, Lowell NE, and Kruk PA: Vitamin E suppresses telomerase activity in ovarian cancer cells. Cancer Detect Prev 31, 119-128, 2007. (Pubitemid 46669813)
179. Bermudez Y, Ahmadi S, Lowell NE, and Kruk PA: Vitamin E suppresses telomerase activity in ovarian cancer cells. Cancer Detect Prev 31, 119-128, 2007. (Pubitemid 46669813)
180. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, et al.: Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301, 39-51, 2009.
181. Ni R, Nishikawa Y, and Carr BI: Cell growth inhibition by a novel vitamin K is associated with induction of protein tyrosine phosphorylation. J Biol Chem 273, 9906-9911, 1998. (Pubitemid 28183089)
182. Wu FY, Liao WC, and Chang HM: Comparison of antitumor activity of vitamins K1, K2, and K3 on human tumor cells by two (MTT and SRB) cell viability assays. Life Sci 52, 1797-1804, 1993.
183. Oztopcu P, Kabadere S, Mercangoz A, and Uyar R: Comparison of vitamins K1, K2 and K3 effects on growth of rat glioma and human glioblastoma multiforme cells in vitro. Acta Neurol Belg 104, 106-110, 2004.
184. Carr BI: Suppression of DCP/PIVKA-2 and alpha-fetoprotein levels in human hepatocellular carcinoma (HCC) by high doses of vitamin K1 (VK1). Hepatology 24, 887-887, 1996.
185. Sun L, Yoshii Y, Miyagi K, and Ishida A: Proliferation inhibition of glioma cells by vitamin K2. No Shinkei Geka 27, 119-125, 1999. (Pubitemid 29093376)
186. Takami A, Nakao S, Ontachi Y, Yamauchi H, and Matsuda T: Successful therapy of myelodysplastic syndrome with menatetrenone, a vitamin K2 analog. Int J Hematol 69, 24-26, 1999.
187. Miyazawa K, Yaguchi M, Funato K, Gotoh A, Kawanishi Y, et al.: Apoptosis/differentiation-inducing effects of vitamin K2 on HL-60 cells: dichotomous nature of vitamin K2 in leukemia cells. Leukemia 15, 1111-1117, 2001. (Pubitemid 32717282)
188. Yaguchi M, Miyazawa K, Katagiri T, Nishimaki J, Kizaki M, et al.: Vitamin K2 and its derivatives induce apoptosis in leukemia cells and enhance the effect of all-trans retinoic acid. Leukemia 11, 779-787, 1997. (Pubitemid 27279724)
189. Cantoni O, Fiorani M, Cattabeni F, and Bellomo G: DNA Breakage caused by hydrogen-peroxide produced during the metabolism of 2-methyl-1,4-naphthoquinone (menadione) does not contribute to the cytotoxic action of the quinone. Biochem Pharmacol 42, S220-S222, 1991.
190. Lamson DW and Plaza SM: The anticancer effects of vitamin K. Altern Med Rev 8, 303-318, 2003. (Pubitemid 37099889)
191. Sata N, Klonowski Stumpe H, Han B, Haussinger D, and Niederau C: Menadione induces both necrosis and apoptosis in rat pancreatic acinar AR4-2J cells. Free Radical Biol Med 23, 844-850, 1997. (Pubitemid 27402609)
192. Nutter LM, Cheng AL, Hung HL, Hsieh RK, Ngo EO, et al.: Menadione-Spectrum of anticancer activity and effects on nucleotide-metabolism in human neoplastic cell-lines. Biochemical Pharmacology 41, 1283-1292, 1991.
193. Wu FYH, Chang NT, Chen WJ, and Juan CC: Vitamin-K3-induced cell-cycle arrest and apoptotic cell-death are accompanied by altered expression of c-fos and c-myc in nasopharyngeal carcinoma cells. Oncogene 8, 2237-2244, 1993.
194. Mitchell JS, Brinkley D, and Haybittle JL: Clinical trial of radiosensitizers, including synkavit and oxygen inhaled at atmospheric pressure. Acta Radiol Ther Phys Biol 3, 329-341, 1965.
195. Juan CC and Wu FY: Vitamin K3 inhibits growth of human hepatoma HepG2 cells by decreasing activities of both p34cdc2 kinase and phosphatase. Biochem Biophys Res Commun 190, 907-913, 1993.
196. Jarabak R and Jarabak J: Effect of Ascorbate on the dt-diaphorase- mediated redox cycling of 2-methyl-1,4-naphthoquinone. Arch Biochem Biophysics 318, 418-423, 1995.
197. Noto V, Taper HS, Jiang YH, Janssens J, Bonte J, et al.: Effects of sodium ascorbate (vitamin C) and 2-methyl-1,4-naphthoquinone (vitamin K3) treatment on human tumor cell growth in vitro. I. Synergism of combined vitamin C and K3 action. Cancer 63, 901-906, 1989.
198. Taper HS, de Gerlache J, Lans M, and Roberfroid M: Non-toxic potentiation of cancer chemotherapy by combined C and K3 vitamin pretreatment. Int J Cancer 40, 575-579, 1987. (Pubitemid 17148749)
199. Jamison JM, Gilloteaux J, Taper HS, and Summers JL: Evaluation of the in vitro and in vivo antitumor activities of vitamin C and K-3 combinations against human prostate cancer. J Nutr 131, 158S-160S, 2001.
200. Venugopal M, Jamison JM,Gilloteaux J, Koch JA, Summers M, et al.: Synergistic antitumour activity of vitamins C and K3 against human prostate carcinoma cell lines. Cell Biol Int 20, 787-797, 1996. (Pubitemid 27075506)
201. Gilloteaux J, Jamison JM, Ervin E, Arnold D, and Summers JL: Scanning electron microscopy and transmission electron microscopy aspects of the synergistic antitumor activity of vitamin C/vitamin K3 combinations against human T24 bladder carcinoma: another kind of cell death? Scanning 20, 208-209, 1998.
202. Taper HS: Reversibility of acid and alkaline deoxyribonuclease deficiency in malignant tumor cells. J Histochem Cytochem 29, 1053-1060, 1981.
203. Fort L, Taper HS, and Brucher JM: Gastric carcinogenesis in rat induced by methylnitrosourea (MNU). Morphology and histochemistry of nucleases. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol 81, 51-62, 1974.
204. Taper HS and Bannasch P: Histochemical correlation between glycogen, nucleic acids and nucleases in pre-neoplastic and neoplastic lesions of rat liver after short-term administration of N-nitrosomorpholine. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol 87, 53-65, 1976.
205. Waxman S and Bruckner H: The enhancement of 5-fluorouracil antimetabolic activity by leucovorin, menadione and alpha-tocopherol. Eur J Cancer Clin Oncol 18, 685-692, 1982. (Pubitemid 12057005)
206. Gold J: In vivo synergy of vitamin K3 and methotrexate in tumor-bearing animals. Cancer Treat Rep 70, 1433-1435, 1986.
207. Nutter LM, Cheng AL, Hung HL, Hsieh RK, Ngo EO, et al.: Menadione: spectrum of anticancer activity and effects on nucleotide metabolism in human neoplastic cell lines. Biochem Pharmacol 41, 1283-1292, 1991.
208. Wang Z, Wang M, Finn F, and Carr BI: The growth inhibitory effects of vitamins K and their actions on gene expression. Hepatology 22, 876-882, 1995.
209. Taper HS, Jamison JM, Gilloteaux J, Gwin CA, Gordon T, et al.: In vivo reactivation of DNases in implanted human prostate tumors after administration of a vitamin C/K-3 combination. J Histochem Cytochem 49, 109-119, 2001.